Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment

• Eric L. Haseltine,

  Affiliation Vertex Pharmaceuticals Incorporated, Boston, Massachussets, United States of America

  ⨯
• Sandra De Meyer,

  Affiliation Janssen Infectious Diseases BVBA, Beerse, Belgium

  ⨯
• Inge Dierynck,

  Affiliation Janssen Infectious Diseases BVBA, Beerse, Belgium

  ⨯
• Doug J. Bartels,

  Affiliation Vertex Pharmaceuticals Incorporated, Boston, Massachussets, United States of America

  ⨯
• Anne Ghys,

  Affiliation Janssen Infectious Diseases BVBA, Beerse, Belgium

  ⨯
• Andrew Davis,

  Affiliation Vertex Pharmaceuticals Incorporated, Boston, Massachussets, United States of America

  ⨯
• Eileen Z. Zhang,

  Affiliation Vertex Pharmaceuticals Incorporated, Boston, Massachussets, United States of America

  ⨯
• Ann M. Tigges,

  Affiliation Vertex Pharmaceuticals Incorporated, Boston, Massachussets, United States of America

  ⨯
• Joan Spanks,

  Affiliation Vertex Pharmaceuticals Incorporated, Boston, Massachussets, United States of America

  ⨯
• Gaston Picchio,

  Affiliation Janssen Research & Development, Titusville, New Jersey, United States of America

  ⨯
• Tara L. Kieffer,

  Affiliation Vertex Pharmaceuticals Incorporated, Boston, Massachussets, United States of America

  ⨯
• James C. Sullivan

  * E-mail: James_Sullivan@vrtx.com

  Affiliation Vertex Pharmaceuticals Incorporated, Boston, Massachussets, United States of America

  ⨯